SCHEMBL162284

SCHEMBL162284

O=C(O)c1cccc2c(O)nc(C(F)(F)c3ccc(F)cn3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
KDM4A O75164 1/20 0.34
RAB9A P51151 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
HIF1AN Q9NWT6 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DHODH Q02127 1/20 0.34
ALDH1A1 P00352 2/20 0.33
NR4A1 P22736 1/20 0.33
NR4A2 P43354 1/20 0.33
NR4A3 Q92570 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
P2RX7 Q99572 2/20 0.33
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
ALB P02768 1/20 0.33
RPS6KB1 P23443 1/20 0.32
AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163623 0.83 NR1H2 (0.35) KDM4EL3MBTL1ALDH1A1LMNA
SCHEMBL162604 0.83 JAK2 (0.34)
SCHEMBL161396 0.82 PDE10A (0.36) KDM4ERAB9AL3MBTL1ALDH1A1PIM1
SCHEMBL158172 0.81 ADORA2A (0.41) KDM4EHPGDALDH1A1
SCHEMBL160537 0.81 ADORA2A (0.33)
SCHEMBL161073 0.80 P2RX3 (0.33)
SCHEMBL160702 0.77 JAK2 (0.44)
SCHEMBL161917 0.75 RPS6KB1 (0.41) PIM1PIM2RPS6KB1AKT1
SCHEMBL161934 0.75 MAPT (0.38) KDM4EALDH1A1PIM1PIM2RPS6KB1
SCHEMBL161445 0.73 KDM4E (0.33) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633207-B2 Quinazoline compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2014-01-21 US disclosed
EP-2611789-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030948-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, TYK2 KDM4E 1840/4885HPGD 2294/4885KDM4A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.